Jianing Fu

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7899271/publications.pdf

Version: 2024-02-01

51 papers	1,280 citations	394421 19 h-index	377865 34 g-index
53 all docs	53 docs citations	53 times ranked	2540 citing authors

#	Article	IF	Citations
1	Defects in Long-Term APC Repopulation Ability of Adult Human Bone Marrow Hematopoietic Stem Cells (HSCs) Compared with Fetal Liver HSCs. Journal of Immunology, 2022, 208, 1652-1663.	0.8	3
2	Editorial: Immunogenomics of Solid Organ and Hematopoietic Stem Cell Transplantation. Frontiers in Immunology, 2022, 13, 878314.	4.8	0
3	Emerging Concepts of Tissue-resident Memory T Cells in Transplantation. Transplantation, 2022, 106, 1132-1142.	1.0	15
4	Lymphohematopoietic graft-versus-host responses promote mixed chimerism in patients receiving intestinal transplantation. Journal of Clinical Investigation, 2021, 131, .	8.2	31
5	Integrated analysis toolset for defining and tracking alloreactive T-cell clones after human solid organ and hematopoietic stem cell transplantation. Software Impacts, 2021, 10, 100142.	1.4	11
6	High Throughput Human T Cell Receptor Sequencing: A New Window Into Repertoire Establishment and Alloreactivity. Frontiers in Immunology, 2021, 12, 777756.	4.8	7
7	Donor T-Cell Repertoire Profiling in Recipient Lymphoid and Parenchyma Organs Reveals GVHD Pathogenesis at Clonal Levels After Bone Marrow Transplantation in Mice. Frontiers in Immunology, 2021, 12, 778996.	4.8	3
8	Cereblon harnesses Myc-dependent bioenergetics and activity of CD8+ T lymphocytes. Blood, 2020, 136, 857-870.	1.4	18
9	SINGLE CELL IMMUNE PROFILING OF HUMAN INTESTINAL ALLOGRAFTS REVEALS HETEROGENEITY AND ALLOREACTIVITY OF RECIPIENT RESIDENT MEMORY T CELLS IN ASSOCIATION WITH GRAFT OUTCOMES. Transplantation, 2020, 104, S72-S73.	1.0	2
10	Computerized quantification of drugs synergism in animal studies or in clinical trials using only ten data points. Synergy, 2019, 9, 100049.	1.1	8
11	210.4: Dynamic repopulation, phenotypic evolution and clonal distribution of recipient B cells and plasma cells in graft mucosa associated with rejection after human intestinal transplantation. Transplantation, 2019, 103, S2-S3.	1.0	0
12	320.6: Potential biomarkers to guide immunosuppression management in intestinal transplant recipients. Transplantation, 2019, 103, S17-S18.	1.0	0
13	Human Intestinal Allografts Contain Functional Hematopoietic Stem and Progenitor Cells that Are Maintained by a Circulating Pool. Cell Stem Cell, 2019, 24, 227-239.e8.	11.1	43
14	CD38-NAD+Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response. Cell Metabolism, 2018, 27, 85-100.e8.	16.2	197
15	Complement C3a and C5a receptors promote GVHD by suppressing mitophagy in recipient dendritic cells. JCI Insight, 2018, 3, .	5.0	22
16	Early expansion of donor-specific Tregs in tolerant kidney transplant recipients. JCI Insight, 2018, 3, .	5.0	54
17	Phenotypic and Clonal Analysis of Recipient B cells and Plasma Cells Entering Graft Mucosa Reveals an Association with Rejection and Evolution towards a Resident Memory Phenotype after Human Intestinal Transplantation. Transplantation, 2018, 102, S15-S16.	1.0	0
18	Role of Graft-derived Graft-versus-Host T cells in Facilitating Multilineage Blood Chimerism after Human Intestinal Transplantation. Transplantation, 2018, 102, S419-S420.	1.0	1

#	Article	IF	Citations
19	Clonal and Functional Analysis Reveals the Capacity of Allograft T cells to Join the Circulating Pool after Human Intestinal Transplantation. Transplantation, 2018, 102, S420-S421.	1.0	1
20	Association of Donor T Cell Repertoire in Host Lymphoid and Target Organs and Gvhd Development. Blood, 2018, 132, 4525-4525.	1.4	0
21	Long-term Persistence of Innate Lymphoid Cells in the Gut After Intestinal Transplantation. Transplantation, 2017, 101, 2449-2454.	1.0	22
22	Differing Mechanisms for Early Versus Persistent Donor T cell Chimerism in Peripheral Blood of Human Intestinal Transplant Recipients. Transplantation, 2017, 101, S63-S64.	1.0	1
23	Phenotype and Function of Human Gut Hematopoietic Stem Cells and Progenitors. Transplantation, 2017, 101, S5-S6.	1.0	0
24	Mixed Chimerism in Peripheral Blood and Allograft after Human Intestinal Transplantation and its Relationship with Clinical Outcomes. Transplantation, 2017, 101, S92.	1.0	0
25	Abstract 4554A: Simple, efficient, and quantitative approach for determination of synergism, additive effect, and antagonism of drugsin vivousing combination index method: a proposition for clinical protocol design and regulatory synergy claims. , 2017, , .		0
26	Drug combination in vivo using combination index method: Taxotere and T607 against colon carcinoma HCT-116 xenograft tumor in nude mice. Synergy, 2016, 3, 15-30.	1.1	45
27	Bidirectional intragraft alloreactivity drives the repopulation of human intestinal allografts and correlates with clinical outcome. Science Immunology, 2016, 1, .	11.9	98
28	T-bet Promotes Acute Graft-versus-Host Disease by Regulating Recipient Hematopoietic Cells in Mice. Journal of Immunology, 2016, 196, 3168-3179.	0.8	9
29	Metabolic reprogramming of alloantigen-activated T cells after hematopoietic cell transplantation. Journal of Clinical Investigation, 2016, 126, 1337-1352.	8.2	107
30	MicroRNA-17-92 controls T-cell responses in graft-versus-host disease and leukemia relapse in mice. Blood, 2015, 126, 1314-1323.	1.4	58
31	Essential Role of Interleukin-12/23p40 in the Development of Graft-versus-Host Disease in Mice. Biology of Blood and Marrow Transplantation, 2015, 21, 1195-1204.	2.0	26
32	T-bet Is Critical for the Development of Acute Graft-versus-Host Disease through Controlling T Cell Differentiation and Function. Journal of Immunology, 2015, 194, 388-397.	0.8	37
33	Targeting Host Complement C3a/C5a Receptors to Control of Acute Graft-Versus-Host Disease in Mice. Blood, 2015, 126, 3076-3076.	1.4	1
34	Inhibition of BTK and ITK with Ibrutinib Is Effective in the Prevention of Chronic Graft-versus-Host Disease in Mice. PLoS ONE, 2015, 10, e0137641.	2.5	84
35	Helper T-Cell Differentiation in Graft-Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation. Archivum Immunologiae Et Therapiae Experimentalis, 2014, 62, 277-301.	2.3	22
36	Reducing CD73 Expression by IL1Î²-Programmed Th17 Cells Improves Immunotherapeutic Control of Tumors. Cancer Research, 2014, 74, 6048-6059.	0.9	49

#	Article	IF	Citations
37	Perfecting Adoptive Cellular Therapy for Graft-Versus-Host Disease: Alloreactive Induced T Regulatory Cells. Blood, 2014, 124, 3813-3813.	1.4	0
38	Microrna-17-92 Cluster: Novel Target for Controlling Gvhd While Preserving GVL Effect. Blood, 2014, 124, 845-845.	1.4	1
39	Allogeneic T Cells Utilize Glycolysis As the Predominant Metabolic Pathway to Induce Acute Graft-Versus-Host Disease. Blood, 2014, 124, 2419-2419.	1.4	2
40	T-Bet Is Critical for the Development of Acute Graft-Versus-Host Disease By Regulating Hematopoietic Antigen Presenting Cells. Blood, 2014, 124, 846-846.	1.4	0
41	Dynamic Change and Impact of Myeloid-Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice. Biology of Blood and Marrow Transplantation, 2013, 19, 692-702.	2.0	61
42	<scp>c</scp>â€<scp>R</scp>el is an essential transcription factor for the development of acute graftâ€versusâ€host disease in mice. European Journal of Immunology, 2013, 43, 2327-2337.	2.9	17
43	Ethaselen: a potent mammalian thioredoxin reductase 1 inhibitor and novel organoselenium anticancer agent. Free Radical Biology and Medicine, 2012, 52, 898-908.	2.9	121
44	T-Bet Is Critical for the Development of Acute Graft-Versus-Host Disease Through Controlling T Cell Differentiation and Function. Blood, 2012, 120, 452-452.	1.4	0
45	Dynamic Changes and Impact of Myeloid Derived Suppressor Cells in Allogeneic Bone Marrow Transplantation in Mice.. Blood, 2012, 120, 2999-2999.	1.4	0
46	Novel mechanism of ethaselen in poorly differentiated colorectal RKO cell growth inhibition: Simultaneous regulation of TrxR transcription, expression and enzyme activity. Differentiation, 2011, 81, 49-56.	1.9	8
47	Selenium-containing thioredoxin reductase inhibitor ethaselen sensitizes non-small cell lung cancer to radiotherapy. Anti-Cancer Drugs, 2011, 22, 732-740.	1.4	29
48	Thioredxin reductase inhibitor ethaselen increases the drug sensitivity of the colon cancer cell line LoVo towards cisplatin via regulation of G1 phase and reversal of G2/M phase arrest. Investigational New Drugs, 2011, 29, 627-636.	2.6	22
49	Abstract 1627: Proteome-wide analysis of echinoderm microtubule associated protein like 4 â€“ anaplastic lymphoma kinase (EML4-ALK) network in lung cancer. , 2011, , .		0
50	Preparation of tri-block copolymer micelles loading novel organoselenium anticancer drug BBSKE and study of tissue distribution of copolymer micelles by imaging in vivo method. International Journal of Pharmaceutics, 2010, 391, 292-304.	5.2	30
51	Drug efficacy and pharmacological action of an organoselenium compound ethaselen, a novel antitumor drug. Journal of Chinese Pharmaceutical Sciences, 2010, 19, .	0.1	9